These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 37287404)

  • 1. A mathematical model of SARS-CoV-2 immunity predicts paxlovid rebound.
    Ranard BL; Chow CC; Megjhani M; Asgari S; Park S; Vodovotz Y
    J Med Virol; 2023 Jun; 95(6):e28854. PubMed ID: 37287404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of SARS-CoV-2 RNA Rebound After Nirmatrelvir/Ritonavir Treatment in Randomized, Double-Blind, Placebo-Controlled Trials - United States and International Sites, 2021-2022.
    Harrington PR; Cong J; Troy SB; Rawson JMO; O'Rear JJ; Valappil TI; McGarry Connelly S; Farley J; Birnkrant D
    MMWR Morb Mortal Wkly Rep; 2023 Dec; 72(51):1365-1370. PubMed ID: 38127674
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of nirmatrelvir for acute SARS-CoV-2 infection with subsequent Long COVID symptoms in an observational cohort study.
    Durstenfeld MS; Peluso MJ; Lin F; Peyser ND; Isasi C; Carton TW; Henrich TJ; Deeks SG; Olgin JE; Pletcher MJ; Beatty AL; Marcus GM; Hsue PY
    J Med Virol; 2024 Jan; 96(1):e29333. PubMed ID: 38175151
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nirmatrelvir combined with ritonavir for preventing and treating COVID-19.
    Reis S; Metzendorf MI; Kuehn R; Popp M; Gagyor I; Kranke P; Meybohm P; Skoetz N; Weibel S
    Cochrane Database Syst Rev; 2022 Sep; 9(9):CD015395. PubMed ID: 36126225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nirmatrelvir combined with ritonavir for preventing and treating COVID-19.
    Reis S; Metzendorf MI; Kuehn R; Popp M; Gagyor I; Kranke P; Meybohm P; Skoetz N; Weibel S
    Cochrane Database Syst Rev; 2023 Nov; 11(11):CD015395. PubMed ID: 38032024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical, Virologic, and Immunologic Evaluation of Symptomatic Coronavirus Disease 2019 Rebound Following Nirmatrelvir/Ritonavir Treatment.
    Epling BP; Rocco JM; Boswell KL; Laidlaw E; Galindo F; Kellogg A; Das S; Roder A; Ghedin E; Kreitman A; Dewar RL; Kelly SEM; Kalish H; Rehman T; Highbarger J; Rupert A; Kocher G; Holbrook MR; Lisco A; Manion M; Koup RA; Sereti I
    Clin Infect Dis; 2023 Feb; 76(4):573-581. PubMed ID: 36200701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Editorial: Rebound COVID-19 and Cessation of Antiviral Treatment for SARS-CoV-2 with Paxlovid and Molnupiravir.
    Parums DV
    Med Sci Monit; 2022 Oct; 28():e938532. PubMed ID: 36181334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paxlovid (Nirmatrelvir/Ritonavir): A new approach to Covid-19 therapy?
    Hashemian SMR; Sheida A; Taghizadieh M; Memar MY; Hamblin MR; Bannazadeh Baghi H; Sadri Nahand J; Asemi Z; Mirzaei H
    Biomed Pharmacother; 2023 Jun; 162():114367. PubMed ID: 37018987
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The efficacy of Paxlovid against COVID-19 is the result of the tight molecular docking between M
    Dawood AA
    Adv Med Sci; 2023 Mar; 68(1):1-9. PubMed ID: 36368287
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molnupiravir and Nirmatrelvir-Ritonavir: Oral Coronavirus Disease 2019 Antiviral Drugs.
    Saravolatz LD; Depcinski S; Sharma M
    Clin Infect Dis; 2023 Jan; 76(1):165-171. PubMed ID: 35245942
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparing molnupiravir and nirmatrelvir/ritonavir efficacy and the effects on SARS-CoV-2 transmission in animal models.
    Cox RM; Lieber CM; Wolf JD; Karimi A; Lieberman NAP; Sticher ZM; Roychoudhury P; Andrews MK; Krueger RE; Natchus MG; Painter GR; Kolykhalov AA; Greninger AL; Plemper RK
    Nat Commun; 2023 Aug; 14(1):4731. PubMed ID: 37550333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of nirmatrelvir-ritonavir on viral clearance and length of hospital stay in patients infected with SARS-CoV-2 omicron variants.
    Wang Y; Zhao D; Chen X; Liu X; Xiao W; Feng L
    Influenza Other Respir Viruses; 2023 Feb; 17(2):e13095. PubMed ID: 36843224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SARS-CoV-2 Rebound With and Without Use of COVID-19 Oral Antivirals.
    Smith DJ; Lambrou A; Patel P
    MMWR Morb Mortal Wkly Rep; 2023 Dec; 72(51):1357-1364. PubMed ID: 38127665
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimizing the use of Paxlovid in clinical practice.
    McCarthy MW
    Drugs Today (Barc); 2022 Nov; 58(11):539-546. PubMed ID: 36422515
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute pulmonary emboli following rebound phenomenon after Nirmatrelvir/Ritonavir treatment for COVID-19.
    Birabaharan M; Martin TCS
    Am J Emerg Med; 2022 Nov; 61():235.e5-235.e6. PubMed ID: 35970690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. COVID-19 Rebound After VV116 vs Nirmatrelvir-Ritonavir Treatment: A Randomized Clinical Trial.
    Yang Z; Xu Y; Zheng R; Ye L; Lv G; Cao Z; Han R; Li M; Zhu Y; Cao Q; Ding Y; Wang J; Tan Y; Liu F; Wei D; Tan W; Jiang W; Sun J; Sun S; Shao J; Deng Y; Gao W; Wang W; Zhao R; Qiu L; Chen E; Zhang X; Wang S; Ning G; Xu Y; Bi Y
    JAMA Netw Open; 2024 Mar; 7(3):e241765. PubMed ID: 38477921
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nirmatrelvir-Ritonavir (Paxlovid) for Mild Coronavirus Disease 2019 (COVID-19) in Pregnancy and Lactation.
    Lin CY; Cassidy AG; Li L; Prahl MK; Golan Y; Gaw SL
    Obstet Gynecol; 2023 May; 141(5):957-960. PubMed ID: 36928334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical discovery and development of nirmatrelvir/ritonavir combinational therapy for the treatment of COVID-19 and the lessons learned from SARS-COV-2 variants.
    Pagliano P; Spera A; Sellitto C; Scarpati G; Folliero V; Piazza O; Franci G; Conti V; Ascione T
    Expert Opin Drug Discov; 2023; 18(12):1301-1311. PubMed ID: 37614103
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic Surveillance of SARS-CoV-2 M
    Lee JT; Yang Q; Gribenko A; Perrin BS; Zhu Y; Cardin R; Liberator PA; Anderson AS; Hao L
    mBio; 2022 Aug; 13(4):e0086922. PubMed ID: 35862764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nirmatrelvir/ritonavir treatment in SARS-CoV-2 positive kidney transplant recipients - a case series with four patients.
    Schneider J; Wobser R; Kühn W; Wagner D; Tanriver Y; Walz G
    BMC Nephrol; 2023 Apr; 24(1):99. PubMed ID: 37061677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.